Eigen Therapeutics, a biotechnology company focused on making cancer therapies more effective, has secured $7.0 million in new investment. The company's mission centers on developing "priming" therapies designed to enhance the efficacy of existing targeted treatments. These therapies work by addressing cancer heterogeneity, making cancer cells more vulnerable to treatment, or by increasing the resilience of healthy cells.
At the core of Eigen's strategy is a high-throughput discovery platform. This platform integrates proprietary machine learning algorithms with advanced robotic systems and specialized laboratory operations software, all developed in-house. It is engineered to explore the vast space of priming therapies, identify novel associations, and discover new classes of drugs that can change a cell's state to improve its susceptibility to targeted therapies.
This $7.0 million capital infusion is a significant step for Eigen Therapeutics, enabling the company to accelerate the development and expansion of its innovative research initiatives. The funds will be strategically deployed to scale its in-house developed systems, further enhance its machine learning capabilities, and advance its pipeline of potential priming therapies.
With this investment, Eigen Therapeutics is positioned to deepen its exploration of the intersection between biology and engineering. The company remains committed to its ultimate goal of developing transformative therapies that make cancer easier to find and eliminate, thereby saving more lives through more effective treatment strategies.
